恩瑞格可以治什么呢？

Iron overload increases the risk of infection, endocrine system damage, vital organ dysfunction, AML transformation in MDS patients, and shortens survival. Iron chelators are currently the mainstream treatment for iron removal. Among them, it is convenient to administer, significantly reduces ferritin levels, and has a definite effect in protecting important target organ systems such as the liver, heart, and endocrine system. It is currently the preferred option for iron removal treatment. Today let’s take a look at what Enrig can treat?

The results of a single-arm, multi-center, prospective clinical study involving 64 AA patients with transfusion-related iron overload confirmed the effectiveness and safety of Enrig in reducing patients' ferritin levels. A prospective, observational study in my country using liver, pancreas, and heart as monitoring indicators confirmed that Enrig can improve organ function in patients with iron overload. The results of the TELESTO study released at the ASH 2018 meeting also proved that Enrige continuously reduces serum ferritin levels, while reducing the risk of heart function damage, liver function damage, transformation to leukemia and other events by 36.4%.

Enrig is mainly suitable for patients with iron accumulation due to long-term blood transfusion (such as those suffering from thalassemia or other rare anemias). It is suitable for children over two years old and adults. Enrige dispersible tablets are oral active chelating agents that are highly selective with iron (Fe3+). It is a ligand with 3 protrusions that binds iron with high affinity in a 2:1 ratio.

Enriga is currently the only oral iron chelator developed by Novartis. It was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions. In December 2012, Enrig was approved by the European Commission for the treatment of chronic iron overload in patients aged 10 years and above with non-transfusion-dependent thalassemia (NTDT) syndrome who require chelation therapy due to contraindications or insufficiency of deferoxamine mesylate therapy. On January 23, 2013, the FDA approved the new indication of Enriga for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) aged 10 years and above.

The above is the content of the indications, I hope it can help you!